A new drug mix helped one man whose lung cancer spread to his brain
Original title: Tislelizumab plus chemotherapy followed by anlotinib maintenance therapy in a patient with extensive-stage small cell lung cancer and intracranial recurrence after palliative whole-brain radiotherapy: a case report and literature review.
How far along is this research?
- Lab cells
- Animals
- Review
- Tested in people
This was tested in people. That is the most reliable kind of research we share.
This is a report on one patient, not a trial that shows it works.
The short version
One man's brain spots went away after he tried a new mix of drugs.
What was studied. Doctors wrote up the story of one patient. He was a 74-year-old man with small cell lung cancer that had spread to his liver and later his brain.
What they found. His cancer came back in his brain five months after whole-brain radiation: Radiation given to the whole brain, rather than aimed at one spot. It is used when there are too many tumors to aim at one at a time. See the glossary ended. He then got the immune drug tislelizumab with two chemo drugs. After that he took anlotinib to hold the cancer back. His scans showed no cancer left, and he had no sign of cancer for 24 months. He lived 67 months in all.
What this means, and what it doesn't
What it could mean: This mix of drugs may be one option to ask about when brain spots come back after radiation. It may be most useful for people who have not had an immune drug before. Your own doctor would need to say if it fits you.
What it doesn't mean: This is one man's story, not a study. One person doing well does not show the drugs will help others. The authors say real trials are needed to test this plan. It is not standard care, and it is not a cure.
Source: PubMed, September 9, 2026 · Read the original
This plain-language summary was written by AI and published automatically after passing our automatic safety checks. How we write.